Overview: Brucella IgM TestIntroduction: The Brucella IgM Test detects IgM antibodies to Brucella, indicating recent infection causing fever, joint pain, or fatigue. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected acute brucellosis.
Other Names: Brucella IgM Assay, Acute Brucellosis Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Brucella antibody testing began in the 1900s with agglutination tests. IgM-specific assays emerged in the 1980s, and by the 2000s, immunoassays improved detection of acute infections.
Purpose: Diagnoses acute brucellosis, guides treatment, and monitors recent infection in patients with fever, joint pain, or fatigue.
Test Parameters: 1. Brucella IgM
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like fever or joint pain, and list occupational exposure or antibiotics.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, joint pain, or occupational exposure (e.g., livestock). Include current medications, especially antibiotics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antibiotic therapy.
Procedural Considerations: Uses an immunoassay to measure Brucella IgM antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Antibiotics or immunosuppression may suppress antibody levels. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm acute brucellosis, prompting immediate antibiotic therapy. Negative results may require IgG or PCR testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation. A rheumatologist referral is advised for joint involvement.
Additional Supporting Tests: Brucella IgG test, blood culture, or PCR to confirm active infection.
Test Limitations: False negatives may occur with very early infection. Results require clinical correlation.
References: IDSA Brucellosis Guidelines, 2023; Clinical Infectious Diseases, Ariza J, 2022.
